Uncategorized

Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE

Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma’s pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton’s tyrosine kinase inhibitor acalabrutinib.

Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE Read More »

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Meiji Seika Pharma Co., Ltd. announced that positive findings from the phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis conducted in the United States and Canada were presented on 12 October at the European Association of Dermatology and Venereology Congress 2023 held in Berlin.

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023 Read More »

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announces significant senior executive hires to further expand services for Novotech’s global biotech clients.

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data Read More »

Scroll to Top